Abstract:Gliomas, a type of primary brain tumor, have emerged as a threat to global mortality due to their high heterogeneity and mortality. A low-grade glioma (LGG), although less aggressive compared with glioblastoma, still exhibits high recurrence and malignant progression. Ubiquitination is one of the most important posttranslational modifications that contribute to carcinogenesis and cancer recurrence. E3-related genes (E3RGs) play essential roles in the process of ubiquitination. Yet, the biological function and clinical significance of E3RGs in LGGs need further exploration. In this study, differentially expressed genes (DEGs) were screened by three differential expression analyses of LGG samples from The Cancer Genome Atlas (TCGA) database. DEGs with prognostic significance were selected by the univariate Cox regression analysis and log-rank statistical test. The LASSO-COX method was performed to identify an E3-related prognostic signature consisting of seven genes AURKA, PCGF2, MAP3K1, TRIM34, PRKN, TLE3, and TRIM17. The Chinese Glioma Genome Atlas (CGGA) dataset was used as the validation cohort. Kaplan-Meier survival analysis showed that LGG patients in the low-risk group had significantly higher overall survival time than those in the high-risk group in both TCGA and CGGA cohorts. Furthermore, multivariate Cox regression analysis revealed that the E3RG signature could be used as an independent prognostic factor. A nomogram based on the E3RG signature was then established and provided the prediction of the 1-, 3-, and 5-year survival probability of patients with LGGs. Moreover, DEGs were analyzed based on the risk signature, on which function analyses were performed. GO and KEGG analyses uncovered gene enrichment in extracellular matrix-related functions and immune-related biological processes in the high-risk group. GSEA revealed high enrichment in pathways that promote tumorigenesis and progression in the high-risk group. Furthermore, ESTIMATE algorithm analysis showed a significant difference in immune and stroma activity between high- and low-risk groups. Positive correlations between the risk signature and the tumor microenvironment immune cell infiltration and immune checkpoint molecules were also observed, implying that patients with the high-risk score may have better responses to immunotherapy. Overall, our findings might provide potential diagnostic and prognostic markers for LGG patients and offer meaningful insight for individualized treatment.

Systematic Identification of UBE2C As a Prognostic Biomarker and Correlated with Immunosuppression and Invasiveness in Glioma

Molecular and Clinical Characterization of UBE2S in Glioma as a Biomarker for Poor Prognosis and Resistance to Chemo-Radiotherapy

Integrative Analysis Reveals the Potential Prognostic Roles and Immunological Values of Unc-5 Netrin Receptor A (UNC5A) in Glioma

Analysis of expression and its clinical significance of UBE2T in lung cancer based on GEO database

Combined Elevation of AURKB and UBE2C Predicts Severe Outcomes and Therapy Resistance in Glioma.

In Silico Analysis of the Correlation of KIF2C with Prognosis and Immune Infiltration in Glioma

Prognosis and clinical features analysis of EMT-related signature and tumor Immune microenvironment in glioma

Prognostic Markers Identification in Glioma by Gene Expression Profile Analysis

An Integrated Immune-Related Bioinformatics Analysis in Glioma: Prognostic Signature's Identification and Multi-Omics Mechanisms' Exploration

Increased UBD Is a Potential Diagnostic and Prognostic Biomarker in Glioma

Identification of an Endoplasmic Reticulum Stress-Related Signature Associated with Clinical Prognosis and Immune Therapy in Glioma

Identification of Immune Cell Infiltration and Immune-Related Genes in the Tumor Microenvironment of Glioblastomas

Identification of Ubiquitination-Related Genes in Human Glioma As Indicators of Patient Prognosis

Prognostic Features of the Tumor Immune Microenvironment in Glioma and Their Clinical Applications: Analysis of Multiple Cohorts

Comprehensive Characterization of a Novel E3-Related Gene Signature with Implications in Prognosis and Immunotherapy of Low-Grade Gliomas.

Expression of overall survival-EMT-immune cell infiltration genes predict the prognosis of glioma

Gene Expression Profiling of Glioblastoma to Recognize Potential Biomarker Candidates

Identification of Key Immune and Cell Cycle Modules and Prognostic Genes for Glioma Patients through Transcriptome Analysis

Identification Of Ugp2 As A Progression Marker That Promotes Cell Growth And Motility In Human Glioma

A combination of RNA-Seq and CHIP-Seq analysis for determining super enhancer- associated genes to evaluate prognosis and immunity of glioma

Identification of novel prognostic targets in glioblastoma using bioinformatics analysis